585 Views

CCC

CCS

CSEM

CANVECTOR

DIABETES CANADA

DIABETE QUÉBEC

THROMBOSIS CANADA

VASCULAR

NURSING

GENERAL

ANGPTL3 INHIBITION

APOCIII INHIBITION

APPETITE REGULATION

ATP-CITRATE LYASE INHIBITOR

BEMPEDOIC ACID

COGNITIVE DECLINE

CVOT

DIABETES PREVENTION & REMISSION

DUAL AGONIST

DYSGLYCEMIA

DYSLIPIDEMIA

ENERGY EXPENDITURE

EVINACUMAB

GLP-1 RA AND GIP/GLP-1 RA DRUGS

GLUCOSE LOWERING & NEW INSULINS

HFPEF

INCLISIRAN

INCRETIN

LIPOPROTEIN (A) INHIBITORS

LOW DENSITY LIPOPROTEIN CHOLESTEROL

META-ANALYSIS

MI AND STROKE PREVENTION

MUVALAPLIN

NASH

NEW INCRETINS

OBESITY

OLPASIRAN

PCSK9 INHIBITORS

PELACARSAN

SAFETY

SGLT2 INHIBITOR DRUGS

THERAPY

TRIGYCERIDE-RICH LIPOPROTEIN CHOLESTEROL

TRIPLE AGONIST

TYPE 1 DIABETES

TYPE 2 DIABETES

Concurrent Session

FUTURE PHARMACOTHERAPY OPTIONS FOR VASCULAR DISEASE

Friday, October 27, 2023

15:15 – 16:15 EST

Location: Palais, 516C

Target Audience: Specialists, research scientists, residents and fellows

Chair(s)

Jeremy Gilbert, MD,FRCPC

MD, FRCPC
Sunnybrook Health Sciences Centre, University of Toronto
University of Toronto

Disclosure(s):

Jeremy Gilbert, MD,FRCPC: Abbott: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Speaker/Honoraria (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Phizer: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

Evaluate studies on novel pharmacotherapies in development to address various vascular diseases;
Describe future medications in diabetes, lipids and obesity; and
Analyze what further research is needed before these pharmacotherapies would be available.

Session Description: In this session, participants will learn about future pharacotherapies that are in development to address various vascular disease states. There will be a focus on upcoming cholesterol lowering medications, and medications to treat diabetes and obesity. There will be a discussion around the potential benefits and side effects of these novel pharmacotherapies.

Presentations:

15:15 – 15:30 EST

FOCUS ON TYPE 2 DIABETES
Presenter: Hertzel Gerstein, MD MSc (he/him/his) – McMaster University
15:30 – 15:45 EST

FOCUS ON DYSLIPIDEMIA
Presenter: G.B. John Mancini, MD, FRCPC, FACP, FACC (he/him/his) – Centre for Cardiovascular Innovation, University of British Columbia
15:45 – 16:00 EST

FOCUS ON OBESITY
Presenter: Megha Poddar – Medical Weight Management Centre of Canada
16:00 – 16:15 EST

PANEL DISCUSSION AND Q&A